Sign in Subscribe
Genetic research

Persistence of Anti-Platelet Factor 4 Antibodies in Vaccine-Induced Immune Thrombocytopenia and Thrombosis

Strategic Insights

— 1 min read

Research from McMaster University has shed light on the persistence of anti-platelet factor 4 antibodies in patients with vaccine-induced immune thrombocytopenia and thrombosis (VITT). According to a study published in the Journal of Thrombosis and Haemostasis, a significant proportion of patients continue to test positive for these antibodies for nearly 3 years post-vaccination. The findings have implications for the management of VITT patients and the potential for long-term anticoagulant or antiplatelet therapy.

Key Takeaways:

  • Researchers from McMaster University followed a Canadian cohort of 30 VITT patients for nearly 3 years, with a median latest follow-up of 715 days post-vaccination.
  • Using Kaplan-Meier analysis, the study found that 65.2% of VITT patients continued to test positive for anti-PF4 antibodies and 34.1% of patients continued to test positive for platelet-activating anti-PF4 antibodies.
  • There were no cases of recurrent thrombosis; however, 7/8 (87.5%) VITT patients with persistent platelet-activating anti-PF4 antibodies remained on anticoagulant or antiplatelet therapy.
  • The complete duration of VITT antibody persistence remains unknown, and further evaluation is required to determine the clinical implications.
  • The study's findings have significant implications for the management of VITT patients and the potential for long-term anticoagulant or antiplatelet therapy.

Statistics:

  • 65.2% of VITT patients continued to test positive for anti-PF4 antibodies.
  • 34.1% of patients continued to test positive for platelet-activating anti-PF4 antibodies.
  • 52.5% of VITT patients remained on anticoagulant therapy.
  • 35.6% of VITT patients remained on antiplatelet therapy.
  • The median latest follow-up was 715 days post-vaccination.

Sources:

  • Journal of Thrombosis and Haemostasis: Persistence of anti-platelet factor 4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis for 3 years. October 2025.
  • NewsRx: Research from McMaster University Yields New Findings on Gene Therapy (Persistence of anti-platelet factor 4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis for 3 years). Gene Therapy Weekly. October 16, 2025; p 721.
  • Publisher contact information for the Journal of Thrombosis and Haemostasis: Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA.

Read more